Hematologic Malignancies

Researcher Spotlight setREVStartSize({c: 'rev_slider_74_10',rl:,el:,gw:,gh:,type:'hero',justify:'',layout:'fullwidth',mh:"320"}); var revapi74, tpj; function revinit_revslider7410() { jQuery(function() { tpj = jQuery; revapi74 = tpj("#rev_slider_74_10"); if(revapi74==undefined || revapi74.revolution == undefined){ revslider_showDoubleJqueryError("rev_slider_74_10"); }else{ revapi74.revolution({ sliderType:"hero", sliderLayout:"fullwidth", visibilityLevels:",1184,980,767", gridwidth:"1170,970,750,320", gridheight:"320,320,226,94", minHeight:320, spinner:"spinner0", perspectiveType:"local", responsiveLevels:",1184,980,767", progressBar:{disableProgressBar:true}, navigation: { onHoverStop:false }, fallbacks: { allowHTML5AutoPlayOnAndroid:true }, }); } }); } // End of RevInitScript var once_revslider7410 = false; if (document.readyState === "loading") {document.addEventListener('readystatechange',function() { if((document.readyState === "interactive" || document.readyState === "complete") && !once_revslider7410 ) { once_revslider7410 = true; revinit_revslider7410();}});} else {once_revslider7410...

PRESS RELEASE Allyson Price, PA-C, Honored With The Mary Pazdur Award for Excellence in Advanced Practice in Oncology by APSHO Allyson Price, PA-C, formerly of The University of Texas MD Anderson Cancer Center, was presented with the fourth annual award by the Advanced Practitioner Society for Hematology and Oncology (APSHO). The award recognizes an exceptional leader,...

Researcher Spotlight: Patrizia Mondello, MD, PhD Mayo Clinic, Rochester  Follicular lymphoma (FL) is generally slow-growing cancer with an overall favorable prognosis. One subset, known as FL3B, has a distinctly worse clinical outcome with limited treatment options. The same treatments used to manage the other, less aggressive FL subsets are significantly less effective for FL3B. Similarly, the regimens used to treat...

Researcher Spotlight: Lydie Debaize, PhD Dana-Farber Cancer Institute Most patients treated for mantle cell lymphoma (MCL) achieve complete remission. Nevertheless, a significant number of patients will eventually relapse due to the regrowing of rare cancer cells remaining in the body after treatment, which is known as minimal residual disease (MRD). For her LRF research project, Dr. Debaize aims to establish new approaches...

Almost half of patients with hematologic malignancies failed to produce antibodies against SARS-CoV-2 after full vaccination and thus remained at risk for COVID-19 infection. Medscape Medical News

Tranexamic acid prophylaxis did not reduce bleeding among patients with hematologic malignancies and severe thrombocytopenia and may do more harm than good. Medscape Medical News

Non-Hispanic black patients with cancer and patients with hematologic malignancies have a significantly increased risk of death if they develop COVID-19, according to data from a cancer/COVID registry. Medscape Medical News

This Northeast Lymphoma Workshop will be a virtual program to deliver live patient education programming during the coronavirus (COVID-19) outbreak. This program will still provide access to local lymphoma experts, and you can tune in over the phone or online. Please continue to check this page for updates. For updates on digital and rescheduled...

First-degree relatives of a patient with blood cancer are at an increased risk of also being diagnosed, suggesting a shared etiology across hematologic malignancies. Medscape Medical News

Lymphoma Workshop: Understanding Lymphoma Basics and Current Treatment Options Saturday, March 23, 20197:30 AM – 3:15 PM Boston Marriott Copley Place  (click here for directions)110 Huntington AvenueBoston, MA 021163 About The Workshop The Lymphoma Research Foundation’s Lymphoma Workshop provides the latest information about lymphoma, current treatment options and support issues to members of the lymphoma community across the United States....